Profiling antibodies for RSV infection and vaccination
TASK V13: DEEP ANTIBODY PROFILING FOR RSV INFECTION AND VACCINATION
['FUNDING_OTHER'] · BATTELLE CENTERS/PUB HLTH RES & EVALUATN · NIH-10683814
This study is working on new vaccines to help protect against Respiratory Syncytial Virus (RSV), and it's for anyone who wants better ways to prevent this infection, especially for those at risk.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BATTELLE CENTERS/PUB HLTH RES & EVALUATN (nih funded) |
| Locations | 1 site (COLUMBUS, UNITED STATES) |
| Trial ID | NIH-10683814 on ClinicalTrials.gov |
What this research studies
This research focuses on developing and evaluating new vaccine candidates and biologics for Respiratory Syncytial Virus (RSV) infection. It involves conducting feasibility studies and providing essential services for the submission of applications required to bring these vaccines to market. Patients may benefit from advancements in vaccine technology that could lead to more effective prevention strategies against RSV. The research aims to enhance our understanding of antibody responses to RSV, which is crucial for vaccine development.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include infants, young children, and individuals with compromised immune systems who are at higher risk for RSV infection.
Not a fit: Patients who are not at risk for RSV infection or those who have already been vaccinated against RSV may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against RSV, potentially reducing the incidence and severity of infections in vulnerable populations.
How similar studies have performed: Previous research has shown success in developing vaccines for other infectious diseases using similar antibody profiling approaches, indicating a promising avenue for RSV vaccine development.
Where this research is happening
COLUMBUS, UNITED STATES
- BATTELLE CENTERS/PUB HLTH RES & EVALUATN — COLUMBUS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RUDGE, THOMAS — BATTELLE CENTERS/PUB HLTH RES & EVALUATN
- Study coordinator: RUDGE, THOMAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Communicable Diseases, Infectious Disease Pathway, Infectious Diseases, Infectious Disorder, RSV infection